The meta-analysis revealed that patients treated with SGLT2 inhibitors had a reduced risk of AF/AFL compared with placebo (RR 0.86; 95%CI, 0.77–0.95; I2 = 0%; P = 0.003) (Figure 3). This evidence concerns the gene SLC5A2 and atrial fibrillation.